These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33772843)

  • 1. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).
    Kang D; S Coffey C; J Smith B; Yuan Y; Shi Q; Yin J
    Stat Med; 2021 May; 40(12):2893-2921. PubMed ID: 33772843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
    Chen N; Lee JJ
    Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.
    Zhang J; Lin R; Chen X; Yan F
    Clin Trials; 2024 Jun; 21(3):308-321. PubMed ID: 38243401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian local exchangeability design for phase II basket trials.
    Liu Y; Kane M; Esserman D; Blaha O; Zelterman D; Wei W
    Stat Med; 2022 Sep; 41(22):4367-4384. PubMed ID: 35777367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
    Kaizer A; Zabor E; Nie L; Hobbs B
    PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering.
    Serra A; Mozgunov P; Jaki T
    Stat Med; 2023 Jul; 42(16):2841-2854. PubMed ID: 37158302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isotonic design for single-arm biomarker stratified trials.
    Li L; Ivanova A
    Stat Methods Med Res; 2024 Jun; 33(6):945-952. PubMed ID: 38573793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian single-arm phase II trial designs with time-to-event endpoints.
    Wu J; Pan H; Hsu CW
    Pharm Stat; 2021 Nov; 20(6):1235-1248. PubMed ID: 34085764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints.
    Shi H; Yin G
    Biometrics; 2018 Sep; 74(3):1055-1064. PubMed ID: 29466612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.
    Chen N; Lee JJ
    Biom J; 2019 Sep; 61(5):1219-1231. PubMed ID: 30506747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints.
    Zhao Y; Tang RS; Du Y; Yuan Y
    Biometrics; 2023 Jun; 79(2):1459-1471. PubMed ID: 35546501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol.
    Yu Z; Wu L; Bunn V; Li Q; Lin J
    Ther Innov Regul Sci; 2023 Jul; 57(4):823-838. PubMed ID: 36871111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian sample size determination in basket trials borrowing information between subsets.
    Zheng H; Grayling MJ; Mozgunov P; Jaki T; Wason JMS
    Biostatistics; 2023 Oct; 24(4):1000-1016. PubMed ID: 35993875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
    Ji Z; Lin J; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints.
    He T; Liu R; Liu M; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):567-581. PubMed ID: 36000260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.